Novavax, Inc (NVAX) concluded trading on Wednesday at a closing price of $7.47, with 14.72 million shares of worth about $109.93 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -26.62% during that period and on April 23, 2025 the price saw a gain of about 19.52%. Currently the company’s common shares owned by public are about 160.42M shares, out of which, 146.57M shares are available for trading.
Stock saw a price change of 16.90% in past 5 days and over the past one month there was a price change of -2.86%. Year-to-date (YTD), NVAX shares are showing a performance of -7.09% which increased to 88.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.90 but also hit the highest price of $23.86 during that period. The average intraday trading volume for Novavax, Inc shares is 4.77 million. The stock is currently trading 17.18% above its 20-day simple moving average (SMA20), while that difference is up 2.59% for SMA50 and it goes to -24.87% lower than SMA200.
Novavax, Inc (NASDAQ: NVAX) currently have 160.42M outstanding shares and institutions hold larger chunk of about 59.66% of that.
The stock has a current market capitalization of $1.20B and its 3Y-monthly beta is at 3.14. It has posted earnings per share of -$1.32 in the same period. It has Quick Ratio of 0.97. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVAX, volatility over the week remained 6.68% while standing at 9.44% over the month.
Stock’s fiscal year EPS is expected to rise by 141.58% while it is estimated to decrease by -31.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on February 28, 2025 offering a Buy rating for the stock and assigned a target price of $19 to it. Coverage by JP Morgan stated Novavax, Inc (NVAX) stock as an Underweight in their note to investors on July 30, 2024, suggesting a price target of $8 for the stock. On May 10, 2024, JP Morgan Upgrade their recommendations, while on May 10, 2024, BofA Securities Upgrade their ratings for the stock with a price target of $12. Stock get a Buy rating from B. Riley Securities on August 09, 2023.
